Last updated on November 2019

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis


Brief description of study

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis.

Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis.

CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Clinical Study Identifier: NCT02158858

Find a site near you

Start Over

UCLA Medical Center

Los Angeles, CA United States
  Connect »

St. Paul's Hospital

Vancouver, BC Canada
  Connect »

Horizon Oncology Center

Lafayette, IN United States
  Connect »

Gabrail Cancer Center

Canton, OH United States
  Connect »

MD Anderson Cancer Center

Houston, TX United States
  Connect »